Hear Insights from Big Pharma Panelists at RESI Europe

21 Feb

By Claire Jeong, Director of Research, Asia BD, LSN


Life Science Nation is busily preparing for our inaugural RESI Europe event at Vienna, Austria on Monday, March 25th, we are excited to announce our Big Pharma panel! There is no doubt that major pharmaceuticals are continuing to explore creative approaches in partnering with early-stage companies, extending beyond the scope of traditional therapeutics. Companies fully understand the value of developing strategic partnerships with big pharma, but it can be a challenge to get in front of the right team.

As companies want to better understand the implications of partnering with big pharma, this panel has been one of our most popular topics since the inception of RESI – here is our lineup of panelists:

Florence Dal Degan, R&D Innovation Sourcing Director at Novo Nordisk

Florence Dal Degan joined Novo Nordisk A/S in May 2016 as R&D Innovation Sourcing Director. The R&D Innovation Sourcing team of Novo Nordisk is global, with a presence at the Danish Headquarters, as well as a regional presence in Shanghai, Boston, New-York and Paris. Florence is based in Paris and is responsible for search and evaluation of new opportunities within Europe and Middle-East across the therapeutic areas that Novo Nordisk is dedicated to, such as diabetes, obesity, NASH, chronic cardiovascular diseases, nephropathy and haemophilia. Florence has a PhD in biochemistry from The National Institute of Agronomy (Agro-Paris Tech, France). She has over 20 years of experience in Research and Development in academic, biotech and pharma environments. Since 2000, Florence has worked with drug discovery and early development and has held several positions as group leader within R&D. She has been working with external innovation since 2012.

Olaf Koenig, Director, International Business Development at Amgen

Olaf Koenig joined Amgen’s Global Business Development team in May 2017. He is Director, International Business Development and responsible for ex-US business development transactions. He is based in Amgen’s European Headquarter in Rotkreuz, Switzerland. He has over 20 years of international experience in a variety of business development and commercial roles, and a track record of leading and closing of several in-licensing, out-licensing and M&A transactions. Prior to joining Amgen, Olaf was Vice President, Business Development & New Product Planning Europe at Daiichi Sankyo. Before joining Daiichi Sankyo, he served as Director Business Development at Merck KGaA. Olaf began his career as Product Manager at Molecular Simulations in Cambridge, UK. Olaf holds a PhD in Chemistry from the University of Berne, Switzerland.

Natalia Novac, Director, Emerging Technology & Innovation, Corporate Business Development at Eli Lilly & Co

Natalia Novac is a part of the Emerging Technology and Innovation Group and is responsible for search and evaluation of novel healthcare technologies across all Eli Lilly indications in Europe.  Natalia is involved in the scientific evaluation of novel life science assets coming from multiple venture funds where Eli Lilly participates as a limited partner. Natalia is an experienced pharmaceutical industry professional with solid background in oncology, endocrinology, immunology and multiple sclerosis. Natalia has a PhD in molecular biology and MSc in Microbiology. Natalia’s LinkedIn

Chris Church, Manager, Partnering and Strategy at AstraZeneca

Chris joined AstraZeneca in November 2014 as a scientist, team and project leader for cardiovascular, renal and metabolic disease (CVRM) with a focus on obesity and type 2 diabetes. Chris transitioned to the AstraZeneca partnering and strategy team helping to coordinate in and out-licensing opportunities for CVRM together with supporting the local and international biopharma ecosystem.

Prior to joining AstraZeneca, Chris obtained a First Class degree in Molecular and Cellular Biology from the University of Bath, UK and completed a PhD at the University of Oxford and MRC Mammalian Genetics Unit, Harwell, UK. This was followed by a postdoctoral position at Yale University, USA and MBA with the Open University.

In case you are curious about what the panel discussion will look like, here is a recap of the Big Pharma panel during RESI SF 2018 (although many different topics will be addressed in the upcoming panel).

If you are not signed up for RESI Europe yet, we hope you can join us and meet companies/investors that fit your partnering objectives and strategies!

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: